Burden Of Advanced Breast Cancer For Patients And Caregiver In Europe: Comparisons Of Two Treatment Forms Of Vinorelbine, Oral And Intravenous

Barni, Sandro; Mouysset, Jean-Loup; Sediva, Marcela; Zamagni, Claudio; Garau, Isabel; Feier, B; Berdeaux, G; Mercier, Florence

doi:10.1016/j.jval.2015.09.1263

Value in Health

2015

DOI: 10.1016/j.jval.2015.09.1263

|View full text |Cite

Burden Of Advanced Breast Cancer For Patients And Caregiver In Europe: Comparisons Of Two Treatment Forms Of Vinorelbine, Oral And Intravenous

Sandro Barni

Jean-Loup Mouysset²,

Marcela Sediva

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is available in both intravenous (IV) and oral formulations and it is indicated for use in the treatment of MBC as a single agent or in combination (5). The oral formulation (Navelbine ® Oral) is considered as an economically viable treatment by health care systems, with a low toxicity profile and good tumour control (6).…”

mentioning

confidence: 99%

Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study

et al. 2020

View full text Add to dashboard Cite

Background/Aim: Vinorelbine is indicated for use in the treatment of MBC as a single agent or in combination but there is little real world data on this molecule and even less on its oral form. We exploited the Unicancer Epidemiology Strategy Medical-Economics (ESME) metastatic breast cancer (MBC) database to investigate current patterns of use of oral vinorelbine (OV), as well as outcomes of patients receiving this drug. Patients and Methods: Data were collected retrospectively from women and men treated for MBC between 2008 and 2014 at one of 18 French Comprehensive Cancer Centres. The efficacy of OV was evaluated in terms of progression-free (PFS) and overall survival (OS) and treatment duration. The population and patterns of OV usage were also described. Results: A total of 1806 patients (11% of the ESME MBC database)were included in this analysis. OV was prescribed as monotherapy (46%) or in combination (29%), especially with capecitabine. mainly in later treatment lines. Median PFS was 3.3 months: 2.9 months for single agent, 3.6 months for combination therapy. Median OS was 40.9 months. Conclusion: Real-world data offer complementary results to the data from traditional clinical trials, but they concern a much larger population. In this ESME MBC cohort, OV was

show abstract

mentioning

confidence: 99%

Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study

et al. 2020

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Burden Of Advanced Breast Cancer For Patients And Caregiver In Europe: Comparisons Of Two Treatment Forms Of Vinorelbine, Oral And Intravenous

Cited by 1 publication

References 0 publications

Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study

Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study

Contact Info

Product

Resources

About